Search

Your search keyword '"Sugawara, S."' showing total 706 results

Search Constraints

Start Over You searched for: Author "Sugawara, S." Remove constraint Author: "Sugawara, S." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
706 results on '"Sugawara, S."'

Search Results

1. Demonstration of nuclear gamma-ray polarimetry based on a multi-layer CdTe Compton Camera

3. Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

5. Comparison of Cerebral Blood Flow Patterns in Patients with Phantom Bite Syndrome with Their Corresponding Clinical Features

8. Reverberation Measurements of the Inner Radius of the Dust Torus in 17 Seyfert Galaxies

9. Inter-Band Effects of Magnetic Field on Hall Conductivity in Multi Layered Massless Dirac Fermion System $\alpha$-(BEDT-TTF)$_2$I$_3$

10. Spin and Valley Splittings in Multilayered Massless Dirac Fermion System

11. Effects of the Zero-Mode Landau Level on Inter-Layer Magnetoresistance in Multilayer Massless Dirac Fermion Systems

12. Pharmacotherapeutic outcomes in atypical odontalgia: determinants of pain relief

13. COORDINATED UPPER-TROPOSPHERE-TO-STRATOSPHERE BALLOON EXPERIMENT IN BIAK

15. Clinical characteristics and course of oral somatic delusions: a retrospective chart review of 606 cases in 5 years

16. Novel multiplex analyses reveal disparate natural killer cell signalling pathway activation during lentivirus infection

18. MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)

19. P1.15-11 Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study

20. PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

21. EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

22. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study

23. 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)

25. 77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors

26. 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

30. 1332P A randomized phase II trial of standard versus low-dose nab-paclitaxel for previously treated advanced non-small cell lung cancer (JMTO LC14-01)

31. LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

34. Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis

36. Construction of superconducting magnet system for the J-PARC neutrino beam line

37. Test results of superconducting magnets for the J-PARC neutrino beam line

38. P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis

39. P76.61 Long Follow up Study of Comparing Erlotinib (ER) with Gefitinib (GE) for Previously Treated Advanced Non-Small Cell Lung Cancer: WJOG5108LFS

40. FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial)

41. P89.06 Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer

42. FP14.02 A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC

43. OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer

44. Age and gravitational separation of the stratospheric air over Indonesia

45. 382MO The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)

46. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

47. Production and performance of the LHC interaction region quadrupoles at KEK

48. 8-kA HTS current leads for 1.9 K test facility at KEK

50. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer

Catalog

Books, media, physical & digital resources